Format

Send to

Choose Destination
Anaerobe. 2016 Aug;40:54-7. doi: 10.1016/j.anaerobe.2016.05.008. Epub 2016 May 11.

Administration of probiotic kefir to mice with Clostridium difficile infection exacerbates disease.

Author information

1
Texas Children's Microbiome Center, Department of Pathology, Texas Children's Hospital, 1102 Bates Ave., Houston, TX, USA; Department of Pathology & Immunology, Baylor College of Medicine, One Baylor Plaza, Houston, TX, USA. Electronic address: spinler@bcm.edu.
2
Texas Children's Microbiome Center, Department of Pathology, Texas Children's Hospital, 1102 Bates Ave., Houston, TX, USA; Department of Pathology & Immunology, Baylor College of Medicine, One Baylor Plaza, Houston, TX, USA.
3
Department of Molecular Virology & Microbiology, Baylor College of Medicine, Houston, TX 77030, USA.

Abstract

Lifeway(®) kefir, a fermented milk product containing 12 probiotic organisms, is reported to show promise as an alternative to fecal microbiota transplantation for recurrent Clostridium difficile infection (CDI). We employed a murine CDI model to study the probiotic protective mechanisms and unexpectedly determined that kefir drastically increased disease severity. Our results emphasize the need for further independent clinical testing of kefir as alternative therapy in recurrent CDI.

KEYWORDS:

Clostridium difficile; Fecal microbiota transplantation; Kefir; Probiotic; Toxin

PMID:
27180007
PMCID:
PMC4969211
DOI:
10.1016/j.anaerobe.2016.05.008
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Elsevier Science Icon for PubMed Central
Loading ...
Support Center